Proteomarin

Proteomarine is a Russian biotechnology company and a subsidiary of Artgen Biotech focused on developing a novel therapeutic platform based on shark-derived nanobodies (vNAR). These variable fragments of shark antibodies are significantly smaller and more stable than conventional human antibodies, allowing for high specificity, improved bioavailability, and less invasive administration routes such as subcutaneous or intranasal. The company's pipeline includes candidates targeting PD-L1 for oncology and PCSK9 for hypercholesterolemia, as well as programs for COVID-19. Proteomarine is a resident of the Skolkovo Innovation Center and leverages its unique platform to address socially significant diseases through next-generation biopharmaceuticals.